Here are four things to know.
1. The study involved 240 healthy volunteers and was designed to demonstrate the GI safety superiority of ATB-346 compared to naproxen, the most prescribed nonsteroidal anti-inflammatory drug in the U.S.
2. ATB-346 is a hydrogen sulfide-releasing derivative of naproxen. While NSAIDs are the most commonly used therapy for osteoarthritis and are widely used in a variety of other conditions, their use is associated with a high incidence of GI ulceration and bleeding.
3. ATB-346 is intended to be an effective, GI-sparing anti-inflammatory/analgesic agent. It is Antibe’s leading drug.
4. Antibe anticipates being able to report top-line results during the week of March 19.
More articles on gastroenterology:
7 statistics on colorectal cancer in the US — 50k+ deaths expected in 2018
The Center for Digestive Health receives ASGE Endoscopy Unit Recognition
4 things to know about the mechanism that may underlie GI, other cancers
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
